Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes

Author:

Pieper Karen S.1,Tsiatis Anastasios A.1,Davidian Marie1,Hasselblad Vic1,Kleiman Neal S.1,Boersma Eric1,Chang Wei-Ching1,Griffin Jeffrey1,Armstrong Paul W.1,Califf Robert M.1,Harrington Robert A.1

Affiliation:

1. From the Duke Clinical Research Institute and Departments of Medicine (K.S.P., J.G., R.M.C., R.A.H.) and Genomics and Biostatistics (V.H.), Duke University Medical Center, Durham, NC; Department of Statistics (A.A.T., M.D.), North Carolina State University, Raleigh, NC; Baylor College of Medicine/Texas Medical Center (N.S.K.), Houston, Tex; Erasmus Medical Center (E.B.), Rotterdam, the Netherlands; and the University of Alberta (W-C.C., P.W.A.), Edmonton, Alberta, Canada.

Abstract

Background— Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used only in acute coronary syndrome patients undergoing percutaneous coronary intervention, supporting data from randomized clinical trials are tenuous. The assumption that these agents are useful only in conjunction with percutaneous coronary intervention is based primarily on inappropriate subgroup analyses performed across the glycoprotein IIb/IIIa inhibitor trials. Methods and Results— We describe the problems with these analytical techniques and demonstrate that different approaches to the question can result in opposing answers. Conclusions— Clinical-practice decisions and practice guidelines should be based on overall trial results and not analyses of post-randomization subgroups.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3